article thumbnail

30-year risk of cardiovascular disease may help inform blood pressure treatment decisions

Science Daily - Heart Disease

According to a new study, both 30-year risk for cardiovascular disease in addition to 10-year risk may be considered in making decisions about when to initiate high blood pressure medication.

article thumbnail

Stress and cardiovascular disease: an update

Nature Reviews - Cardiology

Nature Reviews Cardiology, Published online: 02 May 2024; doi:10.1038/s41569-024-01024-y Physiological responses to stress are thought to increase the risk of cardiovascular disease via haemodynamic, vascular and immune perturbations.

article thumbnail

30-year risk of cardiovascular disease may help inform blood pressure treatment decisions

American Heart News - Heart News

Research Highlights: A comparison of two tools for calculating cardiovascular disease risk found that if only the current 10-year risk thresholds are applied, fewer adults may be recommended for blood pressure-lowering medication. The tools, The.

article thumbnail

Perinatal Depression Tied to Increased Risk of Midlife Cardiovascular Disease

Med Page Today

(MedPage Today) -- Women with perinatal depression (PND) had a higher risk of cardiovascular disease (CVD) in middle adulthood than matched parous women without PND, a Swedish nationwide study found. Over a mean of 10.4 years, women with PND had.

article thumbnail

Population shifts, risk factors may triple U.S. cardiovascular disease costs by 2050

Science Daily - Heart Disease

Driven by an older, more diverse population, along with a significant increase in risk factors including high blood pressure and obesity, total costs related to cardiovascular disease (CVD) conditions are likely to triple by 2050, according to recent projections. At least 6 in 10 U.S. trillion price tag in direct and indirect costs.

article thumbnail

Autoimmune diseases and atherosclerotic cardiovascular disease

Nature Reviews - Cardiology

Nature Reviews Cardiology, Published online: 27 June 2024; doi:10.1038/s41569-024-01045-7 In this Review, Porsch and Binder discuss the evidence for and mechanisms of the increased and premature risk of atherosclerotic cardiovascular disease in patients with autoimmune disease, with particular focus on systemic lupus erythematosus and rheumatoid arthritis. (..)

article thumbnail

Colchicine in atherosclerotic cardiovascular disease

Heart BMJ

Results from a meta-analysis of these trials demonstrate that colchicine reduces the risk of recurrent major adverse cardiovascular events (MACEs) by 25%, leading to its recent approval by the Food and Drug Administration for the treatment and prevention of cardiovascular disease.